Surgery in Patients With Hemophilia and Inhibitors: A Review of the Norwegian Experience With FEIBA

Seminars in Hematology

Volumn 43, Issue SUPPL. 4, 2006, Pages

  Tjønnfjord, Geir E ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANALGESIC AGENT; ANTIBODY; ANTIBODY INHIBITOR; DIURETIC AGENT; NITRATE; OPIATE; PROTHROMBIN COMPLEX; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG TOLERABILITY; HEART INFARCTION; HEMOPHILIA A; HEMOSTASIS; HUMAN; IMMUNOPATHOLOGY; MAJOR SURGERY; MINOR SURGERY; NORWAY; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PRIORITY JOURNAL; SIGMOIDECTOMY; SURGICAL TECHNIQUE;

ADULT; AGED; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; BLOOD LOSS, SURGICAL; COAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOSTASIS, SURGICAL; HUMANS; MIDDLE AGED; NORWAY; PREMEDICATION; TREATMENT OUTCOME;

EID: 33646246176     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2006.03.003     Document Type: Article

References (19)

1. Ehrenforth S., Kreuz W., Scharrer I., Linde R., Funk M., Güngör T., et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339 (1992) 594-598
2. Sjamsoedin L.J.M., Heijnen L., Mauser-Bunschoten E.P., van Geijlswijk J.L., van Houwelingen H., van Asten P., et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 305 (1981) 717-721
3. Bech R.B.M., Nielsen L., Falch J.F., Glazer S., and Hedner U. Evaluation of efficacy of recombinant factor VIIa in 149 patients treated for critical bleeds. Blood 84 (1994) 68a (abstr 262)
4. Rodriguez-Merchan E.C., and Rocino A. Literature review of surgery management in inhibitor patients. Haemophilia 10 suppl 2 (2004) 22-29
5. Hilgartner M.W., and Knatterud G.L. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 61 (1983) 36-40
6. Negrier C., Goudemand J., Sultan Y., Bertrand M., Rothschild C., Lauroua P., and French FEIBA Study Group. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 77 (1997) 1113-1119 Factor Eight Bypassing Activity
7. Faradji A., Bonnomet F., Lecocq J., Grunebaum L., Desprez D., Kern O., et al. Knee joint arthroplasty in a patient with haemophilia A and high inhibitor titre using recombinant factor VIIa (NovoSeven). A new case report and review of the literature. Haemophilia 7 (2001) 321-326
8. Hedner U., Glazer S., Pingel K., Alberts K.A., Blombäck M., Schulman S., et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 2 (1988) 1193
9. Heisel M.A., Gomperts E.D., McComb J.G., and Hilgartner M. Use of activated prothrombin complex concentrate over multiple surgical episodes in a hemophilic child with an inhibitor. J Pediatr 102 (1983) 951-954
10. Hutchinson R.J., Penner J.A., and Hensinger R.N. Anti-inhibitor coagulant complex (Autoplex) in hemophilia inhibitor patients undergoing synovectomy. Pediatrics 71 (1983) 631-633
11. Hvid I., and Rodriguez-Merchan E.C. Orthopaedic surgery in haemophilic patients with inhibitors. An overview. Haemophilia 8 (2002) 288-291
12. Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost 26 (2000) 425-432
13. O'Marcaigh A.S., Schmalz B.J., Shaughnessy W.J., and Gilchrist G.S. Successful hemostasis during a major orthopedic operation by using recombinant activated factor VII in a patient with severe hemophilia A and a potent inhibitor. Mayo Clin Proc 69 (1994) 641-644
14. Rodriguez-Merchan E.C., Wiedel J.D., Wallny T., Hvid I., Berntorp E., Rivard G.-E., et al. Elective orthopaedic surgery for inhibitor patients. Haemophilia 9 (2003) 625-631
15. Schulman S., Lindstedt M., Alberts K.A., and Agren P.H. Recombinant factor VIIa in multiple surgery. Thromb Haemost 71 (1994) 154
16. Blatt P.M., White II G.C., McMillan C.W., and Roberts H.R. Treatment of anti-factor VIII antibodies. Thromb Haemost 38 (1977) 514-523
17. Blatt P.M., Menache D., and Roberts H.R. A survey of the effectiveness of prothrombin complex concentrates in controlling hemorrhage in patients with hemophilia and anti-factor VIII antibodies. Thromb Haemost 44 (1980) 39-42
18. Penner J.A. Treatment of inhibitor patients with activated prothrombin complex concentrates. Prog Clin Biol Res 150 (1984) 291-308
19. Tjønnfjord G.E., Brinch L., Gedde-Dahl T., and Brosstad F.R. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia 10 (2004) 174-178